Analytical Methodologies Supporting Robust Nitrosamine Control Strategies in Drug Development Landscape

The presence of N-nitrosamine impurities, recognized for their mutagenic potential, represents a critical challenge within the pharmaceutical industry. To effectively mitigate this risk, strict adherence to comprehensive nitrosamine risk management strategies, in alignment with regulatory frameworks such as ICH M7 (R1), guidelines issued by the European Medicines Agency (EMA) and FDA, is imperative for all commercial drug substances and finished products. Central to these strategies is the thorough investigation of potential sources of vulnerable amines and nitrites, rigorous evaluation of secondary amine intermediates, and systematic assessment of the propensity for nitrosamine formation under both synthetic reaction conditions, formulation, and long-term storage. These measures are essential to ensure that a thorough risk assessment is performed for nitrosamines in the pharmaceutical development space. For the identified risks, confirmatory testing is performed to generate data for comparison to the established daily acceptable intake (AI) thresholds. Such evaluations often necessitate the deployment of highly sensitive and robust analytical methodologies capable of quantifying secondary amine precursors and nitrosamines at trace levels. In the current presentation, we would like to provide a holistic view of the analytical methodology toolbox consisting of techniques each bringing in a unique capability to address the challenges in analyzing nitrosamines or secondary amines in both drug substance and drug product.